A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides.

ACE ACE2 DX600 Gallium PET Radiopeptide SARS-CoV-2

Journal

EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946

Informations de publication

Date de publication:
19 Apr 2023
Historique:
received: 12 12 2022
accepted: 29 03 2023
medline: 19 4 2023
pubmed: 19 4 2023
entrez: 19 04 2023
Statut: epublish

Résumé

The angiotensin converting enzyme-2 (ACE2)-entry receptor of SARS-CoV-2-and its homologue, the angiotensin-converting enzyme (ACE), play a pivotal role in maintaining cardiovascular homeostasis. Potential changes in ACE2 expression levels and dynamics after SARS-CoV-2 infection have been barely investigated. The aim of this study was to develop an ACE2-targeting imaging agent as a noninvasive imaging tool to determine ACE2 regulation. DOTA-DX600, NODAGA-DX600 and HBED-CC-DX600 were obtained through custom synthesis and labeled with gallium-67 (T The highest molar activity was obtained for [ This study demonstrated ACE2 selectivity for all radiopeptides. [

Identifiants

pubmed: 37074529
doi: 10.1186/s13550-023-00979-2
pii: 10.1186/s13550-023-00979-2
pmc: PMC10113987
doi:

Types de publication

Journal Article

Langues

eng

Pagination

32

Subventions

Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 4078P0_198274

Informations de copyright

© 2023. The Author(s).

Références

Toxicon. 2014 Nov;90:36-44
pubmed: 25091347
Adv Sci (Weinh). 2021 Aug;8(16):e2100965
pubmed: 34174177
Molecules. 2015 Jul 16;20(7):12913-43
pubmed: 26193247
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
EBioMedicine. 2020 Oct;60:102976
pubmed: 32971472
Front Immunol. 2022 Jan 03;12:809244
pubmed: 35046961
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Circ Res. 2000 Sep 1;87(5):E1-9
pubmed: 10969042
Nat Rev Cardiol. 2010 Jan;7(1):38-47
pubmed: 19935740
Mol Syst Biol. 2020 Jul;16(7):e9610
pubmed: 32715618
RSC Adv. 2017 Oct 24;7(78):49586-49599
pubmed: 29308192
Nucl Med Commun. 2008 Mar;29(3):193-207
pubmed: 18349789
J Biol Chem. 2004 Apr 23;279(17):17996-8007
pubmed: 14754895
Clin Exp Med. 2020 Nov;20(4):493-506
pubmed: 32720223
J Nucl Med. 2021 Nov;62(11):1631-1637
pubmed: 33637588
Cochrane Database Syst Rev. 2008 Oct 08;(4):CD003823
pubmed: 18843651
Sci Adv. 2021 Aug 18;7(34):
pubmed: 34407940
Microorganisms. 2021 Aug 09;9(8):
pubmed: 34442770
Biochemistry. 1971 Oct 26;10(22):4033-9
pubmed: 4334402
ACS Chem Neurosci. 2020 Apr 1;11(7):995-998
pubmed: 32167747
Clin Infect Dis. 2021 Dec 6;73(11):e4154-e4165
pubmed: 33388749
EBioMedicine. 2022 Sep;83:104208
pubmed: 35952496
Int J Hypertens. 2012;2012:307315
pubmed: 22121476
J Mol Biol. 2016 Feb 22;428(4):720-725
pubmed: 26410586
Science. 2005 Sep 16;309(5742):1864-8
pubmed: 16166518
Front Mol Biosci. 2020 Sep 30;7:588618
pubmed: 33195436
Chem Soc Rev. 2014 Jan 7;43(1):260-90
pubmed: 24173525
J Biol Chem. 2000 Oct 27;275(43):33238-43
pubmed: 10924499
Lancet Infect Dis. 2020 Sep;20(9):e238-e244
pubmed: 32628905
J Biol Chem. 2003 May 2;278(18):15532-40
pubmed: 12606557
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Hypertension. 2012 Sep;60(3):730-40
pubmed: 22777933
J Pathol. 2020 Jul;251(3):228-248
pubmed: 32418199

Auteurs

Darja Beyer (D)

Center for Radiopharmaceutical Sciences, ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.

Christian Vaccarin (C)

Center for Radiopharmaceutical Sciences, ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.

Xavier Deupi (X)

Condensed Matter Theory Group, Division of Scientific Computing, Theory, and Data, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.
Laboratory of Biomolecular Research, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.
Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.

Ana Katrina Mapanao (AK)

Center for Radiopharmaceutical Sciences, ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.

Susan Cohrs (S)

Center for Radiopharmaceutical Sciences, ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.

Fan Sozzi-Guo (F)

Center for Radiopharmaceutical Sciences, ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.

Pascal V Grundler (PV)

Center for Radiopharmaceutical Sciences, ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.

Nicholas P van der Meulen (NP)

Center for Radiopharmaceutical Sciences, ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.
Laboratory of Radiochemistry, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.

Jinling Wang (J)

Institute of Organic Chemistry, Department of Chemistry and Applied Biosciences, ETH Zurich, 8093, Zurich, Switzerland.

Matthias Tanriver (M)

Institute of Organic Chemistry, Department of Chemistry and Applied Biosciences, ETH Zurich, 8093, Zurich, Switzerland.

Jeffrey W Bode (JW)

Institute of Organic Chemistry, Department of Chemistry and Applied Biosciences, ETH Zurich, 8093, Zurich, Switzerland.

Roger Schibli (R)

Center for Radiopharmaceutical Sciences, ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, 8093, Zurich, Switzerland.

Cristina Müller (C)

Center for Radiopharmaceutical Sciences, ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland. cristina.mueller@psi.ch.
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, 8093, Zurich, Switzerland. cristina.mueller@psi.ch.

Classifications MeSH